Clinical Trial Update: Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating danvatirsen in combination with pembrolizumab for head and neck squamous cell carcinoma has been terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Danvatirsen (danvatirsen)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Flamingo Therapeutics NV | Conditions: HNSCC | Phase 2 | Status: TERMINATED | Results posted: 2026-01-30